Macrobid vs. Trimethoprim

See how Macrobid and Trimethoprim compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Macrobid is taken twice daily for 7 days, while trimethoprim is taken once or twice daily for a 10-day course.

  • Macrobid should be avoided in people with reduced kidney function, while trimethoprim carries its own risks of high potassium and blood cell changes.

  • Trimethoprim contains no sulfonamide component, making it an option for people with sulfa allergies who cannot take combination antibiotics.

Macrobid vs. Trimethoprim Drug Summary

Macrobid

Macrobid (nitrofurantoin) is a urinary anti-infective that treats acute, uncomplicated UTIs caused by E. coli or S. saprophyticus. It is taken as a capsule twice a day for seven days and works almost entirely within the urinary tract, with little effect elsewhere in the body.

Trimethoprim

Trimethoprim is a urinary anti-infective that blocks bacterial folate production to treat acute, uncomplicated UTIs from E. coli and several other bacteria. It comes as a tablet taken once or twice daily for a 10-day course and lacks the sulfa component found in combination antibiotics.

Macrobid vs. Trimethoprim Side Effects

Macrobid

Most common
nausea (up to 8%)
headache (up to 6%)
flatulence (up to 1.5%)
vaginal infections (up to 1.2%)

Trimethoprim

Most common
rash (2.9% to 6.7%)
nausea (rate not specified)
pruritus (rate not specified)
vomiting (rate not specified)

Macrobid vs. Trimethoprim Dosage

Macrobid

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 100 mg every 12 hours Days 1-7
Maximum dose 100 mg every 12 hours Same as starting
Dose changes None Fixed dose

Trimethoprim

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 100 mg every 12 hours Days 1-10
Maximum dose 200 mg once daily Days 1-10
Dose changes 1 increase As tolerated

Macrobid vs. Trimethoprim Indications

Macrobid

Macrobid is FDA-approved for acute, uncomplicated urinary tract infections caused by E. coli or S. saprophyticus. It is also used off-label at low doses for long-term prevention of recurrent UTIs, though it is not approved for kidney infections or for use in children under 12.

  • Acute uncomplicated UTI (cystitis) from E. coli or S. saprophyticus

  • Off-label: long-term low-dose prophylaxis for recurrent UTIs

  • Not approved for pyelonephritis or kidney abscess

  • Not approved for children under 12 or infants under 1 month

Trimethoprim

Trimethoprim is FDA-approved for acute, uncomplicated UTIs caused by E. coli and several other bacteria, including Proteus and Klebsiella. It is also used off-label to prevent recurrent UTIs and, combined with dapsone, to prevent Pneumocystis pneumonia, though it is not approved for infants under 2 months.

  • Acute uncomplicated UTI from E. coli, Proteus, Klebsiella, and others

  • Off-label: prevention of recurrent UTIs

  • Off-label: PCP prophylaxis in combination with dapsone

  • Not approved for infants younger than 2 months

Macrobid vs. Trimethoprim Pros and Cons

Macrobid

Macrobid has remained reliably effective against E. coli despite decades of widespread use, largely because it concentrates in urine rather than the bloodstream. That same low systemic absorption limits its use to lower urinary tract infections and makes kidney function a key safety consideration.

Pros

  • Still reliably effective against E. coli after decades of use

  • Concentrates in urine, so it causes fewer systemic side effects

  • FDA-approved since 1990 with a long track record

  • Also used off-label for long-term UTI prevention

Cons

  • Contraindicated with reduced kidney function (CrCl under 60)

  • Risk of pulmonary toxicity, including fibrosis, with long-term use

  • Risk of liver toxicity, including hepatitis

  • Contraindicated in late pregnancy (38 to 42 weeks)

Trimethoprim

Trimethoprim works well against a slightly broader range of UTI-causing bacteria and offers a convenient once-daily dosing option. Because it blocks folate metabolism, it carries its own risks, including changes in blood potassium and blood cell counts that Macrobid does not share.

Pros

  • Covers a broader range of bacteria, including Proteus and Klebsiella

  • Available as a once-daily 200 mg dose

  • No sulfonamide component, an option for sulfa-allergic patients

  • Also used off-label for Pneumocystis pneumonia prevention

Cons

  • Risk of hyperkalemia, even without typical risk factors

  • Risk of blood cell disorders, including anemia and low platelets

  • Risk of severe skin reactions, including Stevens-Johnson syndrome

  • Can interfere with certain lab tests, including creatinine measurements

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.